Re: Vivaglobin

[Artie Hansford]

I provided and taught patients in SCIG when working for a home infusion company specializing in IVIG therapy 2 years ago.  I don't work there any longer but assume that SCIG is still being used.  We primarily used Gamimune N 10%.  It worked very well.  What was most impressive is that the patients that had moderate to severe side effects with IVIG could tolerate the SQ route even without premedication!  The patients liked it.  There is also evidence that they maintain a more steady state of IG for longer period of time than the IV route.  Artie Hansford

[EMAIL PROTECTED] wrote:

Yeah everything Marilyn said, LOL. But we do need to be sure to take note of the manufacturers recommendations. Unless you like going off label. There is extensive information specific to this product and the manufacturers directions and dosing and administration at the link below.

 

http://www.fda.gov/cber/label/igsczlb010906LB.pdf

 

Tony West, RN, CRNI
Healix, Inc.
Email: [EMAIL PROTECTED] or [EMAIL PROTECTED]
SMS: [EMAIL PROTECTED]
Cell: 214-674-4848

 

In a message dated 3/7/2006 12:07:41 P.M. Central Standard Time, [EMAIL PROTECTED] writes:

SCIG has been done successfully with PID patients for years. It originated in Europe and a lit search will produce a fairly comprehensive review of the procedures, rates and associated outcomes. Since the SCIG procedure usually requires weekly administration, it is a viable option for those individuals who 1) do not want to miss work/school in order to receive IVIG in a more traditional setting and 2) are motivated to assume responsibility for self administration.. It is also popular choice in peds.

 

In Europe, SCIG is done using a 16% product. A similar product has not been available in the US, so providers have usually opted for a 10% product. The new ZLB Behring product, Vivaglobulin, will be the first 16% SCIG in the US. 

Due to competition within the specialty pharmacy arena, your best & most readily available resources to learn more are a review of the published literature, support from the manufacturer, and the Immune Deficiency Foundation, as they have been investigating SCIG for years and offered a session on it at their national conference last year.

 

M Hanchett RN

Director of Clinical Affairs

IgG America

---

From: [EMAIL PROTECTED] [mailto:[EMAIL PROTECTED] On Behalf Of KayBeth Weibel, CRNI
Sent: Monday, March  06, 2006 1:18 PM
To: [EMAIL PROTECTED]
Subject: Vivaglobin

Hello,

 

I received notice today from the FDA of approval for “First Immune Globulin for Subcutaneous use”, Vivaglobin.  I have not administered IG subcutaneously before.  Does anybody have any experiences or comments?

 

Thanks

 

KayBeth Weibel, RN, CRNI

Director of Nursing Services

Infusion Network

Falmouth, MA 02540

tel (508) 548-4266

fax (508) 540-7549

 

 

Artie Hansford, RN, CRNI
Alta Bates Summit Medical Center
PICC Services
350 Hawthorne Ave, Oakland, CA 94609
510-204-3285 Phone/Pager
510-869-6690 Fax